Anal AIN3, Anal Carcinoma
Conditions
Keywords
anal carcinoma, AIN3, cohort study
Brief summary
Evaluation of the 3-years anal carcinoma (AC) incidence in patient with anal AIN3 lesions, and factors associated with this AC. A retrospective cohort study will be conducted (2000-2013) followed by a prospective cohort study (starting in 2013) with new diagnoses of anal AIN3 lesion. The main outcome is histology proven AC. The 3-years incidence rate of AC will be calculated. Factors associated with AC will be estimated using a multivariate Cox regression model.
Detailed description
Background : Incidence of anal carcinoma (AC) is considerably increasing, but no data on risk of AC in patient with anal AIN3 lesions are available, nor french recommendations about screening and treatment of anal AIN3 lesions. Objective : Evaluation of the AC incidence in patient with anal AIN3 lesions, and factors associated with this AC. Population : Patients with a diagnosis of anal AIN3 lesion will be included and followed for 3 years. Patients with past history of AC won't be included. Study design : Retrospective cohort study will be conducted from 2000 using diagnostic codes of anal AIN3 lesion in histo-pathology departments. Then a prospective cohort study will be conducted with new diagnoses of anal AIN3 lesion. Outcome : The main outcome is histology proven AC. AC identification can be done either by using diagnostic codes of AC in histo-pathology departments (for retrospective cases), or prospectively. Statistics : The incidence rate of AC will be calculated. Factors associated with AC will be estimated using a multivariate Cox regression model. Number of patients : 1000 Number of centers : 35 Length of follow-up: 3 years at least Length of study : 3 years of inclusion and 3 years of follow-up at least
Interventions
None listed
Sponsors
Société Nationale Française de Gastroentérologie
French Society of Coloproctology
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be included in the cohort, patients have to: \- have an anal AIN3 (including Bowen's disease) diagnosed by histology (screening population, post-operative discovery…) * Aposteriori for patients with a history of anal AIN3 complicated or not by an anal cancer. These cases will be identified from data bases of anatomopathology laboratories in hospitals since January 1st 2000. * At the diagnostic for the new anal AIN3 Units care involved in the study are those involved in the follow-up of patients with anal pathologies en France, especially anal cancer. Samples are analyzed by the laboratories of anatomopathology of the hospitals where the patients are diagnosed. These points make the histological data bases reliable and allow clearly identifying cases of anal ain3 retrospectively since 2000. Taking in account the number and quality of the units care involved in the study and the way cases are identified, we think our recruitment will be exhaustive in France, to limit selection bias. \- Patient's non opposition to study
Exclusion criteria
* history of anal carcinoma without any history of anal AIN3 lesion * impossible follow-up for the duration of the study (3 years or more) * patient aged under 18
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| at least one anal cancer | 3-year incidence of anal carcinoma | the first diagnosis of anal carcinoma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observance | 3 years | Observance defined by at least one consult a year, in case of history anal dysplasia, or 2 consults a year, in case of persistence of anal dysplasia |
| patient's feelings about his therapeutic care and impact on his emotional life | 3 years | Patient's feelings about his therapeutic care and impact on his emotional life will be evaluated with a single question with an analogical visual scale from 0 (I'm feeling very bad) to 10 (I'm feeling very good) |
Countries
France
Contacts
Primary ContactLaurent Abramowitz, MD
Backup ContactCharlotte Bord, MD
Outcome results
None listed